HRAS and colorectal cancer: The results showed that RGD-p21Ras-scFv significantly reduced the phosphorylation of MEK-ERK/PI3K-AKT and inhibited the activation of MEK-ERK/PI3K-AKT signaling pathway in KRAS wild-type and mutant colorectal cancer cell lines, and KRAS (G12C) inhibitors only inhibited KRASG12C mutant colorectal cancer cell lines (Fig. 5B F, Supplementary Fig. 2B-F).